Understanding the Prolaris Report

Understanding the Prolaris Report
Watch the “Understanding the Prolaris Report” video for a comprehensive explanation of each section of the Prolaris Report.

Prolaris® explains the behavior of the tumor to provide the risk of Disease Specific Mortality (DSM) and metastasis.

Click the number of each section to learn more.

Interactive Report Guide

Tap on each section of the sample Prolaris Biopsy Report to get a description of the section.

Interactive Report Guide

Hover/tap on each section of the sample Prolaris Biopsy Report to get a description of the section.

Active Surveillance

Men identified as being safe for active surveillance may be spared unnecessary treatment, significantly impacting their quality of life.

Single-Modal Treatment

Men who are NOT considered safe for active surveillance are identified as candidates for single-modal therapy, which is defined as one therapy planned at the treatment onset.

Multi-Modal Treatment

Men who are not considered safe to pursue single-modal treatment are identified as candidates for multi-modal therapy, which is defined as either radiation with androgen deprivation or surgery with intensified therapy per guideline recommendations.

Risk When PursuingActive Surveillance

Patients with a 10-year risk of DSM within the green box are considered candidates for AS. This threshold was validated on conservatively managed patients with DSM as the primary outcome.

Risk When PursuingActive Treatment

Patients with a 10-year risk of metastasis within the blue box are considered candidates for single-modal treatment. This threshold was validated on patients treated with single modal therapy with METs as the primary outcome.

ProlarisMolecular Score

The Prolaris Molecular Score is calculated by measuring the expression of 31 cell cycle progression (CCP) genes in the tumor. This predicts the behavior of the tumor. The majority of Prolaris Molecular Scores fall between 1-11, with a higher score indicating more aggressive cancer.

Risk Assessment

Clinical variables and the Prolaris Molecular Score are combined to calculate a patient’s risk assessment.

Risk Stratification Details

The patient’s risk of Disease Specific Mortality or metastasis is represented with a person icon. This person is compared to other patients within their NCCN risk group. The average DSM risk of each NCCN category is shown with a triangle. The active surveillance threshold is indicated by a dashed line The multi-modal threshold is indicated with a dotted line.

Test Description and References

The test description and references are provided on the final page of the report.

Sources:

  1. Cuzick J, Berney DM, Fisher G, et al; Transatlantic Prostate Group. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer. 2012;106(6):1095-1099.
  2. Data on file. Salt Lake City, UT: Myriad Genetic Laboratories, Inc.
  3. Lin DW, et al. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urologic Oncology: Seminars and original investigations. 2018.